What is the Galleri blood test?

The Galleri blood test is a cancer-spotting blood test developed by GRAIL that analyzes DNA fragments shed by cancer cells to detect over 50 types of cancer early.

Did the Galleri blood test succeed in its latest trial?

In a recent large-scale trial, the Galleri blood test did not meet its goal of significantly reducing late-stage cancer diagnoses, representing a setback for the technology.

Can early detection of cancer with blood tests guarantee improved survival rates?

It remains a contested question whether early detection through blood tests like Galleri can lead to improved survival rates, with concerns about detecting harmless tumors and the inherent lethality of certain cancers.

Home / Health / Cancer Blood Test Faces Setback: Early Detection Hopes Dimmed

Cancer Blood Test Faces Setback: Early Detection Hopes Dimmed

27 Feb

•

Summary

Galleri blood test failed to significantly reduce late-stage cancer diagnoses in a large trial.
The test analyzes DNA fragments shed by cancer cells for early detection.
Concerns remain whether early detection with these tests improves survival rates.

Cancer Blood Test Faces Setback: Early Detection Hopes Dimmed

GRAIL's ambitious Galleri blood test, aimed at detecting over 50 cancer types early, faced a significant hurdle. A three-year trial with 142,000 individuals aged 50-77, where half received the Galleri screening alongside standard tests, did not achieve its goal of reducing late-stage diagnoses. The full trial results are anticipated in May and may offer a more detailed view of the test's effectiveness for specific cancers and populations. This news impacts the field of early cancer detection, where competitors are also developing novel blood tests. The underlying principle involves analyzing DNA fragments or proteins shed by cancer cells. Galleri, available since 2021, has undergone extensive study, previously showing it could spot about 40% of cancers diagnosed within a year, though with a notable rate of false alarms.